A Phase 3 interventional study of Suzetrigine (SUZ) and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.
Among the 10 studies testing suzetrigine in Acute Pain, this one has the largest enrollment, is one of 2 that started in 2022, is one of 2 in phase 3, and was the 4th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+
Soheil Ashkani Esfahani
Ages 18–75
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2022.
This study's enrollment of 1,118 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 165 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated, this one has the largest enrollment, is one of 3 that started in 2022, is one of 2 in phase 3, and was the 7th registered.
Vertex Pharmaceuticals Incorporated’s Acute Pain studies by the year they started, since 2017.
2 of the studies testing suzetrigine in Acute Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
| NCT07795827Soheil Ashkani EsfahaniSuzetrigine for Postoperative Pain After Total Ankle Replacement | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing suzetrigine in Acute Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 10 in Acute Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Key Inclusion Criteria:
Before Surgery
After Surgery
Key Exclusion Criteria:
Before Surgery
After Surgery
Other protocol defined Inclusion/Exclusion criteria may apply.
Participants received placebo matched to Suzetrigine (SUZ) and Hydrocodone bitartrate/acetaminophen (HB/APAP) for 48 hours.
Drug: Placebo (matched to SUZ) · Drug: Placebo (matched to HB/APAP)
Participants received HB 5 milligrams (mg)/ APAP 325 mg every 6 hours (q6h) for 48 hours.
Drug: HB/APAP · Drug: Placebo (matched to SUZ)
Participants received SUZ \[100 mg as first dose, followed by 50 mg every 12 hours (q12h)\] for 48 hours.
Drug: Suzetrigine (SUZ) · Drug: Placebo (matched to HB/APAP)
Tablets for oral administration.
Also known as: VX-548
Drug pages: Hydrocodone · Acetaminophen
Capsules for oral administration.
Placebo matched to SUZ for oral administration.
Placebo matched to HB/APAP for oral administration.
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each postdose time point (using pain rating score range: 0 =no pain to 10 =worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
Time frame: 0 to 48 hours After First Dose of Study Drug
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to HB/APAP
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point (using pain rating score range: 0 =no pain to 10 =worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
Time frame: 0 to 48 hours After First Dose of Study Drug
Time to Greater Than or Equal to (≥) 2-point Reduction in NPRS, SUZ Compared to Placebo
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥2-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 2-point reduction in NPRS scores from baseline. Participants who did not reach at least a 2-point reduction in NPRS from baseline by 48 hours were censored at 48 hours.
Time frame: From Baseline Up to 48 Hours After First Dose of Study Drug
Time to ≥1-point Reduction in NPRS, SUZ Compared to Placebo
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥1-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 1-point reduction in NPRS scores from baseline. Participants who did not reach at least a 1-point reduction in NPRS from baseline by 48 hours were censored at 48 hours.
Time frame: From Baseline Up to 48 Hours After First Dose of Study Drug
Percentage of Participants Reporting Good or Excellent on the Patient Global Assessment (PGA) Scale, SUZ Compared to Placebo
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 4-point Likert scale as: (poor, fair, good, or excellent). Percentage of participants who reported good or excellent on the PGA scale were reported. Participants who discontinued study drug or had missing PGA at 48 hours were considered to not have reported good or excellent on the PGA.
Time frame: At 48 hours
Incidence of Vomiting or Nausea, SUZ Compared to HB/APAP
The incidence with the events of vomiting or nausea during the specified time frame was reported.
Time frame: From Baseline Up to Day 19
Time-weighted SPID as Recorded on the NPRS From 0 to 24 Hours (SPID24), SUZ Compared to Placebo
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference (PID) was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point (NPRS range: 0 = no pain to 10 = worst possible pain). Time-weighted SPID was calculated as the sum of the PIDs at each post-dose time point multiplied by the time interval (in hours) between each time point. SPID 24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).
Time frame: 0 to 24 Hours After First Dose of Study Drug
Time to First Use of Rescue Medication, SUZ Compared to Placebo
Time to first use of rescue medication is the time from the first dose of study drug until the first use of rescue medication. Participants who did not take any rescue medication within 48 hours were censored at 48 hours.
Time frame: 0 to 48 Hours After First Dose of Study Drug
Percentage of Participants Using Rescue Medication From 0 to 48 Hours, SUZ Compared to Placebo
Time frame: 0 to 48 Hours After First Dose of Study Drug
Total Rescue Medication Usage, SUZ Compared to Placebo
Time frame: 0 to 48 Hours After First Dose of Study Drug
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 19
| Milestone | Placebo | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) |
|---|---|---|---|
| Started | 223 | 448 | 447 |
| Safety set | 222 | 448 | 448 |
| Completed | 206 | 426 | 423 |
| Not completed | 17 | 22 | 24 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 10 | 17 | 19 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Other non-compliance | 0 | 1 | 2 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 |
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each postdose time point (using pain rating score range: 0 =no pain to 10 =worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
| units on a scale | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo | 70.1 ± 6.1 | 118.4 ± 4.3 |
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point (using pain rating score range: 0 =no pain to 10 =worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
| units on a scale | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) |
|---|---|---|
| Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to HB/APAP | 111.8 ± 4.3 | 118.4 ± 4.3 |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥2-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 2-point reduction in NPRS scores from baseline. Participants who did not reach at least a 2-point reduction in NPRS from baseline by 48 hours were censored at 48 hours.
| minutes | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Time to Greater Than or Equal to (≥) 2-point Reduction in NPRS, SUZ Compared to Placebo | 480 (477 to 705) | 119 (90 to 180) |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The time to ≥1-point reduction in NPRS from baseline was the time elapsed from the first dose of study drug until the first time the participant had at least a 1-point reduction in NPRS scores from baseline. Participants who did not reach at least a 1-point reduction in NPRS from baseline by 48 hours were censored at 48 hours.
| minutes | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Time to ≥1-point Reduction in NPRS, SUZ Compared to Placebo | 91 (60 to 180) | 34 (32 to 55) |
The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 4-point Likert scale as: (poor, fair, good, or excellent). Percentage of participants who reported good or excellent on the PGA scale were reported. Participants who discontinued study drug or had missing PGA at 48 hours were considered to not have reported good or excellent on the PGA.
| percentage of participants | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Percentage of Participants Reporting Good or Excellent on the Patient Global Assessment (PGA) Scale, SUZ Compared to Placebo | 49.8 | 67.8 |
The incidence with the events of vomiting or nausea during the specified time frame was reported.
| percentage of participants | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) |
|---|---|---|
| Incidence of Vomiting or Nausea, SUZ Compared to HB/APAP | 33.5 | 20.3 |
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference (PID) was calculated by subtracting the baseline pain intensity score from the pain intensity score at each post dose time point (NPRS range: 0 = no pain to 10 = worst possible pain). Time-weighted SPID was calculated as the sum of the PIDs at each post-dose time point multiplied by the time interval (in hours) between each time point. SPID 24 was calculated from 0 to 24 hours and the score range was -240 (worst score) to 240 (best score).
| units on a scale | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Time-weighted SPID as Recorded on the NPRS From 0 to 24 Hours (SPID24), SUZ Compared to Placebo | 24.2 ± 2.8 | 48.0 ± 2.0 |
Time to first use of rescue medication is the time from the first dose of study drug until the first use of rescue medication. Participants who did not take any rescue medication within 48 hours were censored at 48 hours.
| minutes | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Time to First Use of Rescue Medication, SUZ Compared to Placebo | 115 (100 to 132) | 186 (158 to 212) |
| percentage of participants | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Percentage of Participants Using Rescue Medication From 0 to 48 Hours, SUZ Compared to Placebo | 87.9 | 81.0 |
| milligram | Placebo | Suzetrigine (SUZ) |
|---|---|---|
| Total Rescue Medication Usage, SUZ Compared to Placebo | 1200 (0 to 3200) | 800 (0 to 3200) |
| Participants | Placebo | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) |
|---|---|---|---|
| Participants with TEAEs | 125 | 272 | 224 |
| Participants with SAEs | 5 | 7 | 11 |
Collected over Day 1 up to Day 19. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/222 (0.5%) | 5/222 (2.3%) | 94/222 (42.3%) |
| HB/APAP | 0/448 (0%) | 7/448 (1.6%) | 201/448 (44.9%) |
| Suzetrigine (SUZ) | 0/448 (0%) | 11/448 (2.5%) | 146/448 (32.6%) |
| Event | Placebo | HB/APAP | Suzetrigine (SUZ) |
|---|---|---|---|
| Post procedural haematomaInjury, poisoning and procedural complications | 2/222 | 1/448 | 2/448 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/222 | 0/448 | 0/448 |
| Cardiogenic shockCardiac disorders | 1/222 | 0/448 | 0/448 |
| Drug hypersensitivityImmune system disorders | 1/222 | 0/448 | 0/448 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/222 | 0/448 | 0/448 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/222 | 2/448 | 2/448 |
| HypotensionVascular disorders | 1/222 | 0/448 | 0/448 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 0/222 | 2/448 | 0/448 |
| AnaemiaBlood and lymphatic system disorders | 0/222 | 0/448 | 1/448 |
| Intra-abdominal haematomaGastrointestinal disorders | 0/222 | 1/448 | 0/448 |
| Event | Placebo | HB/APAP | Suzetrigine (SUZ) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 56/222 | 147/448 | 85/448 |
| ConstipationGastrointestinal disorders | 24/222 | 39/448 | 47/448 |
| DizzinessNervous system disorders | 17/222 | 24/448 | 18/448 |
| HeadacheNervous system disorders | 11/222 | 32/448 | 19/448 |
| HypotensionVascular disorders | 15/222 | 16/448 | 11/448 |
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Placebo | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) | Total |
|---|---|---|---|---|
| Mean | 41.5 ± 8.5 | 42.1 ± 8.7 | 41.5 ± 9.1 | 41.8 ± 8.8 |
| Sex: Female, Male(Participants) | Placebo | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) | Total |
|---|---|---|---|---|
| Female | 220 | 441 | 437 | 1098 |
| Male | 3 | 7 | 10 | 20 |
| Race/Ethnicity, Customized(Participants) | Placebo | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 73 | 157 | 150 | 380 |
| Not Hispanic or Latino | 150 | 288 | 297 | 735 |
| Missing | 0 | 3 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Placebo | Hydrocodone Bitartrate/Acetaminophen (HB/APAP) | Suzetrigine (SUZ) | Total |
|---|---|---|---|---|
| White | 155 | 316 | 307 | 778 |
| Black or African American | 62 | 114 | 123 | 299 |
| Asian | 0 | 9 | 7 | 16 |
| American Indian or Alaska Native | 1 | 0 | 5 | 6 |
| Native Hawaiian or other Pacific Islander | 1 | 5 | 3 | 9 |
| Other | 2 | 0 | 0 | 2 |
| Multiracial | 2 | 4 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Oct 2022 to primary completion in Aug 2023, 10 months.
Results were first posted in Jul 2025, 1 year 10 months after primary completion. A results delay was requested in Aug 2024.
Of 29 industry-sponsored phase 3 interventional studies under Acute Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 10 months is close to that.
Counting every sponsor, half of 54 studies reached it within 14 months; a quarter within 7 and three quarters within 25.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →